1. 2022-RA-324-ESGO Phase 2 results from the LIO-1 STUDY (NCT04042116; ENGOT-GYN3/AGO/LIO): efficacy and safety of lucitanib + nivolumab in patients with advanced gynaecological malignancies. (20th October 2022) Authors: Concin, Nicole; Patel, Manish R; Makker, Vicky; Oaknin, Ana; Pignata, Sandro; Backes, Floor J; González-Martín, Antonio; Eskander, Ramez N; Pothuri, Bhavana; Richardson, Debra L; Secord, Angeles Alvarez; van Nieuwenhuysen, Els; Liu, Joyce F; Musa, Fernanda; Penson, Richard T; Wride, Kenton; Dusek... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. (March 2015) Authors: Eskander, Ramez N; Tewari, Krishnansu S Journal: Future oncology Issue: Volume 11:Number 6(2015) Page Start: 909 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. (March 2015) Authors: Eskander, Ramez N; Tewari, Krishnansu S Journal: Future oncology Issue: Volume 11:Number 6(2015) Page Start: 909 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. (March 2015) Authors: Eskander, Ramez N; Tewari, Krishnansu S Journal: Future oncology Issue: Volume 11:Number 6(2015) Page Start: 909 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies. Issue 6 (November 2014) Authors: Eskander, Ramez N; Tewari, Krishnansu S Journal: Expert review of clinical pharmacology Issue: Volume 7:Issue 6(2014) Page Start: 847 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Gynecologic oncology : a pocketbook /: a pocketbook. ([2015]) Editors: Eskander, Ramez N; Bristow, Robert E Record Type: Book Extent: 1 online resource (xiii, 427 pages), illustrations (some color) View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer. Issue 4 (7th February 2023) Authors: Hill, Breana L; Graf, Ryon P; Shah, Kunal; Danziger, Natalie; Lin, Douglas I; Quintanilha, Julia; Li, Gerald; Haberberger, James; Ross, Jeffrey S; Santin, Alessandro D; Slomovitz, Brian; Elvin, Julia A; Eskander, Ramez N Journal: International journal of gynecological cancer Issue: Volume 33:Issue 4(2023) Page Start: 504 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Moving beyond cytotoxic drug dosing in ovarian cancer. Issue 10214 (7th December 2019) Authors: Eskander, Ramez N; Monk, Bradley J Journal: Lancet Issue: Volume 394:Issue 10214(2019) Page Start: 2043 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PARP inhibition and synthetic lethality in ovarian cancer. Issue 5 (September 2014) Authors: Eskander, Ramez N; Tewari, Krishnansu S Journal: Expert review of clinical pharmacology Issue: Volume 7:Issue 5(2014) Page Start: 613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗